Thakeb F, Salama Z, Salama H, Abdel Raouf T, Abdel Kader S, Abdel Hamid H
Gastrointestinal Endoscopy Unit, Kasr El Aini Hospital, Cairo University, Egypt.
Endoscopy. 1995 Jun;27(5):358-64. doi: 10.1055/s-2007-1005714.
Recently, tissue adhesive material has been used to improve the initial control of bleeding from huge esophagogastric varices, and to prevent them from rebleeding, in contrast to the conventional sclerotherapy. The present study assessed the value of the combined use of the tissue adhesive substance: N-butyl-2-cyanoacrylate and ethanolamine oleate 5% for management of bleeding esophagogastric varices.
One hundred and fourteen patients with documented active variceal bleeding at the time of endoscopy were alternatively randomized into two groups. The combined therapy group included 58 patients who underwent injection using both cyanoacrylate for large esophageal and gastric varices and a sclerosant agent for remaining varices. The sclerosis, or control, group included 56 patients, who underwent injection with ethanolamine oleate.
This study proved the value of the combined therapy for the initial control of all bleeders (the follow-up period ranged from 12 to 32 months). In the sclerosis group, failure of the initial control of bleeding was reported in two cases (3.6%). Recurrent bleeding occurred in 8.6% in the combined therapy group compared to 25% in the sclerosis group (p < 0.01). Two months of therapy was required to achieve complete eradication of varices in 56.5% and 21.4% in the combined therapy and the sclerosis group, respectively. The mean number of sessions needed until the time of evaluation was 2.4 +/- 1.1 in the combined therapy group versus 5.1 +/- 2.3 sessions in the sclerosis group. The difference showed high statistical significance (p < 0.01). Minor complications occurred less frequently in the combined therapy group. Only one patient in the combined therapy group developed portal pyemia after extension of the tissue adhesive material from the site of injection into the portal vein. This patient died of hepatic failure. The mortality in the combined therapy group was lower than that in the sclerosis group (3.5% and 8.8% respectively, p > 0.05).
The combined use of tissue adhesive and sclerosant materials seems to be the best plan for rapid eradication of esophagogastric varices within a short time, requiring the lowest number of injection sessions and involving minor complications and low mortality.
近来,与传统硬化疗法相比,组织黏合剂已被用于改善对巨大食管胃静脉曲张出血的初始控制,并预防其再次出血。本研究评估了组织黏合剂N - 丁基 - 2 - 氰基丙烯酸酯与5%油酸乙醇胺联合使用在治疗食管胃静脉曲张出血中的价值。
114例在内镜检查时记录有活动性静脉曲张出血的患者被随机分为两组。联合治疗组包括58例患者,他们对大的食管和胃静脉曲张使用氰基丙烯酸酯注射,对其余静脉曲张使用硬化剂注射。硬化治疗组或对照组包括56例患者,他们接受油酸乙醇胺注射。
本研究证明了联合治疗对所有出血者初始控制的价值(随访期为12至32个月)。在硬化治疗组中,有2例(3.6%)报告初始控制出血失败。联合治疗组再出血发生率为8.6%,而硬化治疗组为25%(p < 0.01)。联合治疗组和硬化治疗组分别需要2个月的治疗才能使56.5%和21.4%的患者静脉曲张完全消除。至评估时联合治疗组所需的平均疗程数为2.4 ± 1.1次,而硬化治疗组为5.1 ± 2.3次。差异具有高度统计学意义(p < 0.01)。联合治疗组轻微并发症的发生率较低。联合治疗组只有1例患者在组织黏合剂从注射部位延伸至门静脉后发生门静脉脓毒症。该患者死于肝衰竭。联合治疗组的死亡率低于硬化治疗组(分别为3.5%和8.8%,p > 0.05)。
组织黏合剂与硬化剂联合使用似乎是在短时间内快速消除食管胃静脉曲张的最佳方案,所需注射疗程数最少,并发症轻微,死亡率低。